Ukrainian Journal Health of Woman. 2025. 6(181): 109-125. doi: 10.15574/HW.2025.6(186).109125
Romanenko T. G., Morozova O. V., Staselovych L. Y., Zhaloba H. M., Kononets O. P.
Shupyk National Healthcare University of Ukraine, Kyiv

For citation: Romanenko TG, Morozova OV, Staselovych LY, Zhaloba HM, Kononets OP. (2025). A modern view of preeclampsia: pathogenesis, prognosis, prevention, diagnosis and treatment (clinical lecture with test tasks). Ukrainian Journal Health of Woman. 6(181): 109-125. doi: 10.15574/HW.2025.6(186).109125
Article received: Sep 24, 2025. Accepted for publication: Nov 20, 2025.

Aim – to increase the effectiveness of prediction, prevention, diagnosis and treatment of preeclampsia (PE) according to the obtained modern literature data, thereby reducing the frequency of obstetric and perinatal complications.
Presented are modern data on the etiology, pathogenesis, prediction and prevention of PE according to the recommendations of domestic and foreign protocols, as well as data from the statistical department of the Ministry of Health of Ukraine for the last 10 years from 2012 to 2022, which demonstrate an increase in the frequency of hypertensive disorders during pregnancy, against the background of a decrease in the specific gravity of PE and eclampsia. In 2022-2023, during the war years, a significant increase in the frequency of development of both hypertensive disorders and PE is noted. Data are provided on risk factors for the development of hypertensive disorders during pregnancy, the formation of risk groups, the appointment of modern preventive methods to reduce the frequency and severity of the development of PE. The modern classification of hypertensive disorders during pregnancy and PE is considered. Clinical cases of the course of PE, PE phenotypes and their treatment tactics are presented. The terms and methods of delivery in early and late PE are carefully described.
Conclusions. The management of pregnant women with PE remains a difficult task, requiring modern efforts of obstetrician-gynecologists, including the implementation of new methods of prediction, prevention, diagnosis and treatment of PE, preparation and management of childbirth in these patients.
Keywords: hypertensive disorders, pregnancy, early preeclampsia, late preeclampsia, phenotypes of preeclampsia, fetal growth retardation, placental insufficiency, pathogenesis, prediction, prevention, diagnostics, antihypertensive drugs, terms and methods of delivery, treatment.

REFERENСЕS

1. ACOG. (2020). Gestational Hypertension and Preeclampsia. ACOG Practice Bulletin, Number 222. Obstet Gynecol. 135(6): e237-e260. https://doi.org/10.1097/AOG.0000000000003891; PMid:32443079 PMCid:PMC8907436

2. Bhide A, Acharya G, Baschat A, Bilardo CM, Brezinka C, Cafici D et al. (2021, Aug). ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics. Ultrasound Obstet Gynecol. 58(2): 331-339. https://doi.org/10.1002/uog.23698; PMid:34278615

3. Bilardo CM, Chaoui R, Hyett JA, Kagan KO, Karim JN, Papageorghiou AT et al. (2023, Jan). ISUOG Practice Guidelines (updated): performance of 11-14-week ultrasound scan. Ultrasound Obstet Gynecol. 61(1): 127-143. https://doi.org/10.1002/uog.26106; PMid:36594739 PMCid:PMC10152315

4. Cao L, He B, Zhou Y, Chen T, Gao Y, Yao B. (2024, Jun 21). Utility of uterine artery Doppler ultrasound imaging in predicting preeclampsia during pregnancy: a meta-analysis. Med Ultrason. 26(2): 197-204. https://doi.org/10.11152/mu-4355; PMid:38805623

5. Chappell LC, Cluver CA, Kingdom J, Tong S. (2021). Pre-eclampsia. Lancet. 398(10297): 341-354. https://doi.org/10.1016/S0140-6736(20)32335-7; PMid:34051884

6. Cirkovic A, Garovic V, Milin Lazovic J, Milicevic O, Savic M, Rajovic N et al. (2020, Jul 6). Systematic review supports the role of DNA methylation in the pathophysiology of preeclampsia: a call for analytical and methodological standardization. Biol Sex Differ. 11(1): 36. https://doi.org/10.1186/s13293-020-00313-8; PMid:32631423 PMCid:PMC7336649

7. Cluver CA, Rohwer C, Rohwer AC. (2025, Dec 3). Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic reviews. 12(12): CD001059. https://doi.org/10.1002/14651858.CD001059.pub6; PMid:41330480 PMCid:PMC12672055

8. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM et al. (2021, Sep 28). Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 326(12): 1186-1191. https://doi.org/10.1001/jama.2021.14781; PMid:34581729

9. Dines V, Suvakov S, Kattah A, Vermunt J, Narang K, Jayachandran M et al. (2023, Jan 30). Preeclampsia and the Kidney: Pathophysiology and Clinical Implications. Compr Physiol. 13(1): 4231-4267. https://doi.org/10.1002/cphy.c210051; PMid:36715282

10. Dimitriadis E, Rolnik DL, Zhou W et al. (2023). Pre-eclampsia. Nat Rev Dis Primers. 9(1): 8. https://doi.org/10.1038/s41572-023-00417-6; PMid:36797292

11. Dipali P, Gupta R, Parveen A, Parween S, Poonam P, Choudhary MK. (2025). Prediction of preeclampsia at 11-14 weeks of pregnancy by using FMF score with a history and uterine artery doppler: A prospective study. J Family Med Prim Care. 14(10): 4158-4163. https://doi.org/10.4103/jfmpc.jfmpc_1985_24; PMid:41280603 PMCid:PMC12633984

12. Espinoza J, Vidaeff A, Pettker CM, Simhan H. (2019). Gestational hypertension and preeclampsia. Obstetrics & Gynecology. 133(1): 1-3. https://doi.org/10.1097/AOG.0000000000003018; PMCid:PMC12812992

13. Fetal Medicine Foundation (FMF). Risk for preeclampsia. Desktop, mobile and web app end user licence agreement. URL: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester.

14. Fischer M, Schmutzhard E, Beer R. (2022). Posterior reversible encephalopathy syndrome (PRES) in preeclampsia and eclampsia: a systematic review of the literature. J Neurol. 269(5): 2400-2415. doi: 10.1007/s00415-021-10874-y.

15. Frost A, Agarwal M, Leeson P. (2025). International guidelines for the management of hypertensive disorders of pregnancy: an opportunity to improve the lifelong health of women? Eur J Prev Cardiol. 32(1): zwaf488. https://doi.org/10.1093/eurjpc/zwaf488; PMid:40794599

16. Garovic VD, Dechend R, Easterling T et al. (2022). Hypertension in Pregnancy: A Scientific Statement From the American Heart Association. Hypertension. 79(2): e21-e41. https://doi.org/10.1161/HYP.0000000000000208; PMid:34905954 PMCid:PMC9031058

17. Giannubilo SR, Marzioni D, Tossetta G, Ciavattini A. (2024, Feb 6). HELLP Syndrome and Differential Diagnosis with Other Thrombotic Microangiopathies in Pregnancy. Diagnostics (Basel). 14(4): 352. https://doi.org/10.3390/diagnostics14040352; PMid:38396391 PMCid:PMC10887663

18. Huppertz B. (2018). The Critical Role of Abnormal Trophoblast Development in the Etiology of Preeclampsia. Curr Pharm Biotechnol. 19(10): 771-780. https://doi.org/10.2174/1389201019666180427110547; PMid:29701150 PMCid:PMC6463401

19. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. (2020) Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol. 76(14):1690-1702. https://doi.org/10.1016/j.jacc.2020.08.014; PMid:33004135 PMCid:PMC12042644

20. Javandoust Gharehbagh F, Soltani-Zangbar MS, Yousefzadeh Y. (2024, Aug). Immunological mechanisms in preeclampsia: A narrative review. J Reprod Immunol. 164: 104282. https://doi.org/10.1016/j.jri.2024.104282; PMid:38901108

21. Khalil A, Sotiriadis A, D'Antonio F, Da Silva Costa F, Odibo A, Prefumo F et al. (2024, Jan). ISUOG Practice Guidelines: performance of third-trimester obstetric ultrasound scan. Ultrasound Obstet Gynecol. 63(1): 131-147. https://doi.org/10.1002/uog.27538; PMid:38166001 PMCid:PMC11789108

22. Kinshella M, Sarr C, Sandhi A, Bone J, Vidler M, Moore S, et al. (2022). Calcium for pre-eclampsia prevention: a systematic review and network meta-analysis to guide personalised antenatal care. BJOG. 129: 1833-1843. https://doi.org/10.1111/1471-0528.17222; PMid:35596262

23. Korzeniewski SJ, Sutton E, Escudero C, Roberts JM. (2022, Aug 30). The Global Pregnancy Collaboration (CoLab) symposium on short- and long-term outcomes in offspring whose mothers had preeclampsia: A scoping review of clinical evidence. Front Med (Lausanne). 9: 984291. https://doi.org/10.3389/fmed.2022.984291; PMid:36111112 PMCid:PMC9470009

24. Liu J, Chen Y, Tai ST, Nguyen-Hoang L, Li K, Lin J et al. (2024). First Trimester Preeclampsia Screening and Prevention: Perspective in Chinese Mainland. Maternal Fetal Med. 6(2): 84-91. https://doi.org/10.1097/FM9.0000000000000215; PMid:40432929 PMCid:PMC12106214

25. Loussert L, Dupuis N, Hamdi SM, Guerby P, Vayssière C. (2025). Screening and prevention of preeclampsia using the Fetal Medicine Foundation algorithm. Gynecol Obstet Fertil Senol. 53(2): 76-80. https://doi.org/10.1016/j.gofs.2024.09.007; PMid:39368551

26. Magee LA, Nicolaides KH, von Dadelszen P. (2022). Preeclampsia. N Engl J Med. 386(19): 1817-1832. https://doi.org/10.1056/NEJMra2109523; PMid:35544388

27. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A et al. (2023). 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 41(12): 1874-2071. https://doi.org/10.1097/HJH.0000000000003480; PMid:37345492

28. Martins JG, Miller E, Aboukhater D, Bittner M, Rolnik DL, Kawakita T. (2025). Performance of a first-trimester combined screening for preterm preeclampsia in the United States population using the Fetal Medicine Foundation competing risks model. Am J Obstet Gynecol MFM. 7(12): 101803. https://doi.org/10.1016/j.ajogmf.2025.101803; PMid:41033489

29. Michalczyk M, Celewicz A, Celewicz M, Woźniakowska-Gondek P, Rzepka R. (2020, Oct 5). The Role of Inflammation in the Pathogenesis of Preeclampsia. Mediators Inflamm. 2020: 3864941. https://doi.org/10.1155/2020/3864941; PMid:33082708 PMCid:PMC7556088

30. MOZ Ukrainy. (2022). Hipertenzyvni rozlady pid chas vahitnosti, polohiv ta u pisliapolohovomu periodi. Nakaz MOZ Ukrainy vid 24 sichnia 2022 roku No. 151.

31. MOZ Ukrainy. (2023). Zatrymka rostu ploda. Nakaz MOZ Ukrainy vid 2 zhovtnia 2023 r. No. 1718.

32. NICE. (2019). Hypertension in pregnancy: NG133. (Updated 2023).

33. Ninan N, Ali R, Morfaw F, McDonald SD. (2023). Prevention of pre-eclampsia with aspirin: a systematic review of guidelines and evaluation of the quality of recommendation evidence. Int J Gynaecol Obstet. 161(1): 26-39. https://doi.org/10.1002/ijgo.14471; PMid:36129381

34. Nzelu D, Palmer T, Stott D, Pandya P, Napolitano R, Casagrandi D et al. (2024). First-trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study. BJOG. 131(2): 222-230. https://doi.org/10.1111/1471-0528.17598; PMid:37431533

35. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. (2019). Pre-eclampsia: pathogenesis and diagnostics. Nat Rev Nephrol. 15(5): 275-289. https://doi.org/10.1038/s41581-019-0119-6; PMid:30792480 PMCid:PMC6472952

36. Poon LC, Magee LA, Verlohren S, Shennan A, von Dadelszen P, Sheiner E et al. (2021). A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO. Int J Gynaecol Obstet. 154; Suppl 1: 3-31. https://doi.org/10.1002/ijgo.13763; PMid:34327714 PMCid:PMC9290930

37. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H et al. (2019). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 145; Suppl 1: 1-33. https://doi.org/10.1002/ijgo.12802; PMid:31111484 PMCid:PMC6944283

38. Richards EMF, Giorgione V, Stevens O, Thilaganathan B. (2023, Apr). Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. Am J Obstet Gynecol. 228(4): 395-408. https://doi.org/10.1016/j.ajog.2022.09.046; PMid:36209937

39. Romero R, Jung E, Chaiworapongsa T, Erez O, Gudicha DW, Kim YM et al. (2022, Oct). Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. Am J Obstet Gynecol. 227(4): 615.e1-615.e25. Epub 2022 Sep 3. https://doi.org/10.1016/j.ajog.2022.04.015; PMid:36180175 PMCid:PMC9525890

40. Rottenstreich A. (2024). Controversies and clarifications regarding the role of aspirin in preeclampsia prevention: a focused review. J Clin Med. 13(15): 4427. https://doi.org/10.3390/jcm13154427; PMid:39124694 PMCid:PMC11312818

41. Salomon LJ, Alfirevic Z, Berghella V, Bilardo CM, Chalouhi GE, Da Silva Costa F et al. (2022, Jun). ISUOG Practice Guidelines (updated): performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 59(6): 840-856. doi: 10.1002/uog.24888.
https://doi.org/10.1002/uog.24888
PMid:35592929

42. Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, Glanc P, Khalil A et al. (2019). ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol. 53(1): 7-22. https://doi.org/10.1002/uog.20105; PMid:30320479 PMCid:PMC10183917

43. Stampalija T, Lees C, Ghi T, Cornette J, Gyselaers W, Ferrazzi E et al. (2025, Nov). ISUOG Consensus Statement on maternal hemodynamic assessment in hypertensive disorders of pregnancy and fetal growth restriction. Ultrasound Obstet Gynecol. 66(5): 681-696. https://doi.org/10.1002/uog.70040; PMid:40997762 PMCid:PMC12579779

44. Stepan H, Galindo A, Hund M, Schlembach D, Sillman J et al. (2023, Feb). Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 61(2): 168-180. https://doi.org/10.1002/uog.26032; PMid:35816445

45. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K et al. (2022). Treatment for Mild Chronic Hypertension during Pregnancy (CHAP). N Engl J Med. 386(19): 1781-1792. https://doi.org/10.1056/NEJMoa2201295; PMid:35363951 PMCid:PMC9575330

46. Velegrakis A, Kouvidi E, Fragkiadaki P, Sifakis S. (2023). Predictive value of the sFlt 1/PlGF ratio in women with suspected preeclampsia: An update (Review). International Journal of Molecular Medicine. 52: 89. https://doi.org/10.3892/ijmm.2023.5292; PMid:37594116 PMCid:PMC10500221

47. Wang Y, Guo X, Obore N, Ding H, Wu C, Yu H. (2022). Aspirin for the prevention of preeclampsia: a systematic review and meta-analysis of randomized controlled studies. Front Cardiovasc Med. 9: 936560. https://doi.org/10.3389/fcvm.2022.936560; PMid:36440041 PMCid:PMC9682183

48. Wang Y, Wu S, Zhang D, Jiang W, Zhao G. (2023). Dietary fiber and preeclampsia risk: a meta-analysis of observational studies. Am J Clin Nutr. 118(4): 750-760. https://doi.org/10.1016/j.ajcnut.2023.07.005; PMid:37661101

49. World Health Organization. (2020). WHO recommendations on drug treatment for non-severe hypertension in pregnancy. Geneva: WHO.

50. Yagel S, Cohen SM, Admati I, Skarbianskis N, Solt I, Zeisel A et al. (2023, Dec). Expert review: preeclampsia Type I and Type II. Am J Obstet Gynecol MFM. 5(12): 101203. Epub 2023 Oct 21. https://doi.org/10.1016/j.ajogmf.2023.101203; PMid:37871693